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This report elucidates four aspects of the immunology of pulmonary tuberculosis produced in rabbits: (i) the
virulence of bovine-type tubercle bacilli, strain Ravenel S, (ii) systemic factors influencing the generation of
visible primary pulmonary tubercles, (iii) differences in tuberculin sensitivity of rabbits and humans, and (iv)
the effect of Mycobacterium vaccae immunotherapy on cavitary tuberculosis. Laboratory strain Ravenel S
(ATCC 35720) was not fully virulent. Fully virulent strains produce one visible primary pulmonary tubercle for
each three bacillary units inhaled. Strain ATCC 35720 produced one such tubercle for each 18 to 107 bacillary
units inhaled, indicating that its virulence was reduced by 6- to 36-fold. When a low dose of this Ravenel S
strain was inhaled, the host resistance (measured by the number of inhaled bacilli needed to generate one
visible primary pulmonary tubercle) was increased at least 3.5-fold compared to the host resistance when a
high dose was inhaled. Rabbits and humans differ in the degree and in the maintenance of their dermal
sensitivities to tuberculin. Compared to rabbits, humans are 100 times more sensitive to tuberculin. Also, at
33 weeks rabbits with well-controlled cavitary tuberculosis usually showed a decrease in their tuberculin
reactions of about 50% from peak values, whereas humans with such well-controlled tuberculosis are thought
to maintain strong reactions for many years. These species differences may be due to desensitization to group
II mycobacterial antigens in the rabbits because they have a different diet and a different type of digestive tract.
M. vaccae immunotherapy of rabbits with cavitary tuberculosis produced no statistically significant effects.
Experiments with many more rabbits would be required to prove whether or not such immunotherapy is
beneficial.
In most industrialized nations, tuberculosis (TB) declined
throughout the 20th century, but it has recently reemerged as an
important infectious disease. The increased prevalence is appar-
ently due to (i) a relaxation of public health TB control efforts
(because of other budgetary priorities); (ii) human immunodefi-
ciency virus infection (AIDS), which greatly increases susceptibil-
ity to TB; (iii) increased poverty and homelessness in parts of the
industrialized world; and (iv) the emergence of multidrug-resis-
tant cases (because of inadequate treatment). In developing
countries, TB has always been a common disease, and the above
factors, as well as civil war and famine, have increased its preva-
lence. To control this disease, we need new vaccines and new
antimicrobials supplemented by effective immunotherapy.
The most promising immunotherapeutic agent available to-
day is heat-killed Mycobacterium vaccae, a rapidly growing
bacillus, which was originally found in the pastures of cattle
and in their milk (51). M. vaccae apparently enhances cell-
mediated immunity (i.e., the ability of macrophages to kill
tubercle bacilli) and reduces the tissue-damaging hypersensi-
tivity response to these bacilli (38–40, 42, 48).
This report is a supplement to reference 7. In that reference,
we published descriptions of rabbit cavitary TB without men-
tioning which animals were treated with M. vaccae and which
were controls, because the disease seemed identical in both
groups. Upon reexamination of the data in those experiments
(including some that were not published), we found (i) new
information on the virulence of the Ravenel S strain of bovine-
type tubercle bacilli (section i of Results), (ii) new information
concerning the effects of high vs low doses of inhaled bacilli on
the early immune response (section ii of Results), (iii) new
information about the maintenance of tuberculin sensitivity in
rabbits with cavitary TB (section iii of Results), and (iv) new
information on the effects of M. vaccae immunotherapy on
cavitary TB (section iv of Results).
MATERIALS AND METHODS
Tubercle bacilli. Virulent bovine-type tubercle bacilli, strain Ravenel S, were
obtained from the American Type Culture Collection (ATCC) (ATCC 35720),
grown on Lo¨wenstein-Jensen solid media, and prepared for aerosolization as
described in reference 7. It is a laboratory strain that has been used for over 80
years. In a personal communication from ATCC, we learned that the strain we
received was an original aliquot of the strain obtained in 1985 from the Trudeau
Mycobacterial Culture Collection in Saranac Lake, N.Y. In 1985, it was grown on
Lo¨wenstein-Jensen solid media, suspended in 23 sterile skim milk (made from
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a powder), aliquotted, quick frozen, lyophilized, and stored at 5°C until a vial was
sent to us in 1993.
About three passages of our ATCC strain of Ravenel S on the solid media
were made between experiments I and III. This strain did not lose virulence
during the subculturing between our experiments, because the number of inhaled
bacilli that generated one visible primary pulmonary tubercle, i.e., the “ratio”
(12), did not increase during the 1.5-year lapse of time (see Results).
Rabbits and aerosol infection with virulent bovine-type tubercle bacilli. New
Zealand White rabbits were infected by aerosol with the Ravenel S strain at the
United States Army Medical Research Institute of Infectious Diseases at Fort
Detrick, Frederick, MD (7). The animals used in low-dose experiments I, III, and
IV were commercially available Pasteurella-free New Zealand White rabbits
from Covance Research Products, Inc. (formerly Hazelton Laboratories), Den-
ver, Pa. (7). The animals used in high-dose experiment II were Pasteurella-free
inbred New Zealand White rabbits (strain IIIVO/JU), which should have a high
degree of native resistance to TB (see Results).
In conducting this research, the investigators adhered to reference 34a.
Four experiments were performed, but the rabbits in experiment I did not
receive M. vaccae immunotherapy. In high-dose experiment II almost half of the
rabbits were dead or dying by 9 weeks. In low-dose experiment III, all of the
rabbits survived for 30 to 33 weeks, at which time they were sacrificed. Experi-
ment III provided most of the data analyzed herein.
Tuberculin reactions. Undiluted veterinary tuberculin (0.1 ml) (intradermic
tuberculin, mammalian; Coopers Animal Health, Inc., Kansas City, Kans.; now
available from Symbiotics, San Diego, Calif.) was injected intradermally, and 2
days later the volume of the resulting reaction was measured with calipers (13).
Euthanasia and necropsies. The rabbits were weighed and then sacrificed by
the intravenous injection of 2.5 to 3.0 ml of sodium pentobarbital (65 mg/ml) at
the times listed in Table 1. Necropsy details on these rabbits (except for those
listed in Tables 3 and 5) were presented in reference 7.
Determining the number of primary pulmonary lesions. In low-dose experi-
ment III at 33 weeks, we were usually able to determine the total number of
primary pulmonary lesions, as well as the number of primary lesions that cavi-
tated (Table 4). Such established primary pulmonary lesions did not regress, and
secondary lesions were usually small (or absent) and easily distinguished from
the primary lesions. Some of these lesions had solid caseous centers; some had
liquefied; and still others not only had liquefied but also had eroded bronchi and
formed cavities. In M. vaccae-treated rabbit 2 and control rabbit 5, the primary
cavities gave rise to multiple (loculated) secondary cavities in a cluster that
obscured the primary lesions located there (7). In these two rabbits, we had to
estimate the number of primary lesions from the distribution of other primary
lesions in the same lungs.
In high-dose experiment II, the secondary lesions (which contained no cavi-
ties) were much smaller than the primary lesions because the rabbits were
sacrificed at 18 weeks.
Acid-fast stain for tubercle bacilli. Paraffin-embedded tissue sections were
stained for the bacillus by the Ziehl-Neelsen carbol-fuchsin method and were
counterstained with methylene blue (3).
M. vaccae immunotherapy. Autoclaved M. vaccae (strain NCTC 11659) bacilli
were obtained from J. L. Stanford and G. A. W. Rook, Department of Bacteri-
ology, Windeyer Institute of Medical Sciences, University College London Med-
ical School, London, England (48). The M. vaccae bacilli (109 in 0.1 ml of
diluent) were injected intradermally into the left flank of our tuberculous rabbits
at the times listed in Table 1. Diluent alone was injected into the controls. Since
108 M. vaccae bacilli did not always produce distinct lesions in normal (tuber-
culin-negative) rabbits, we chose 109 bacilli (the human dose) for experiments II
and III. In experiment IV, performed at Texas A & M University, the rabbits
were given 1/10 the human dose of M. vaccae. This was a small pilot-type
experiment with only three M. vaccae-treated rabbits and two controls. The
dermal lesions produced by M. vaccae appeared to be larger in tuberculin-
positive rabbits, but not enough M. vaccae lesions in normal tuberculin-negative
rabbits were evaluated to make an accurate comparison.
Statistics. The TB produced in these rabbits seemed to be influenced by
several factors: (i) the number of primary lesions and the number of these lesions
that formed cavities, (ii) the degree of tuberculin sensitivity, and, possibly, (iii)
the M. vaccae immunotherapy. Multiple linear regression analysis (43, 55) in the
form of y 5 b0 1 b1x1 1 b2x2 enabled us to evaluate relationships among these
factors. In this equation, y is the outcome variable, b0 is the value of y where x1
and x2 are both equal to 0, b1 is the difference between the regression lines
representing the M. vaccae-treated and the control groups, x1 equals 1 for the M.
vaccae-treated group and 0 for the control group, b2 is the slope of the regression
lines, and x2 is the input variable.
For Fig. 1 through 4, we have assumed that the slopes of the regression lines
for the M. vaccae and control groups would be the same. (There was no statis-
tically significant evidence that they were not.) Then, we determined whether the
two regression lines together (representing all 11 or 12 rabbits) showed a statis-
tically significant slope and also whether the difference on the y axis of the
regression lines for M. vaccae-treated and control groups was statistically signif-
icant.
For these analyses, we used (in our mainframe computer) STATA statistical
software, version 5.0 (1997) from Stata, Inc., College Station, Tex.
RESULTS
Rabbits were infected by aerosol with virulent bovine-type
tubercle bacilli, strain Ravenel S (ATCC 35720). In high-dose
experiment II, the rabbits inhaled an average of 5,100 U of one
to three bacilli. In low-dose experiment III, the rabbits inhaled
an average of 420 bacillary units. At 6 to 10 weeks after in-
fection, the lungs of such rabbits are known (from previous
experiments) to contain liquefied caseous and early cavitary
tuberculous lesions, similar to those usually present in immu-
nocompetent patients with TB. Liquefied and cavitary lesions
do not occur in tuberculous mice and only rarely occur in
tuberculous guinea pigs.
The tuberculous rabbits received monthly injections of heat-
killed M. vaccae. These injections began at 5 to 7 weeks (when
cavities were developing) and continued until the animals died
or were sacrificed at 18 or 33 weeks (depending on the exper-
iment). At necropsy, most of the rabbits in these experiments
had cavitary TB (7).
Table 1 summarizes our findings in these two experiments
and lists which rabbits received M. vaccae immunotherapy and
which rabbits did not.
Virulence (for rabbits) of the bovine-type tubercle bacilli,
strain Ravenel S. Counts of the primary pulmonary lesions
indicated that this Ravenel S strain was reduced in virulence by
6- to 36-fold (Table 2). The number of inhaled bacillary units
of one to three bacilli required to produce one primary lesion
(i.e., the ratio) was 107 in high-dose experiment I, 18 in high-
dose experiment II, and 63 in low-dose experiment III (Table
2). If the Ravenel S strain had been fully virulent, only 3
bacillary units would have been required (26, 27). Nonetheless,
this Ravenel S bovine-type bacillus was much more virulent for
rabbits than H37Rv, a common laboratory strain of virulent
human-type bacillus. For H37Rv to produce one primary le-
sion in commercially available New Zealand White rabbits,
about 1,500 inhaled bacillary units would be required (unpub-
lished observations).
The Ravenel S bacilli (ATCC 35720) were not reduced in
virulence by several passages on Lo¨wenstein-Jensen media
during the 1.5-year period between experiments I and III. The
ratio was 107 6 29 in experiment I and 63 6 13 in experiment
III, i.e., an insignificant trend in the opposite direction was
present (Table 2). The inhaled dose for each rabbit was not
determined in experiment IV, performed at Texas A & M
University rather than at the U.S. Army Medical Research
Institute of Infectious Diseases at Fort Detrick (see below).
Therefore, the ratios in experiment IV cannot be accurately
compared to those in the first three experiments.
Ratios are one of the most accurate methods of measuring
the virulence of bovine-type tubercle bacilli in rabbits because
ratios reflect the ability of the bacillus to establish a progressive
disease (12).
Effect of inhaled dose on the initial (very early) immune
response. The rabbits in high-dose experiment II inhaled, on
the average, 5,100 bacillary units and developed 310 visible
primary pulmonary lesions (Table 2). The rabbits in low-dose
experiment III inhaled, on the average, 418 bacillary units and
developed 8.8 primary lesions (Table 2). The ratios, i.e., the
numbers of inhaled bacillary units required to generate one
visible primary lesion (12), were 18.2 and 63.3, respectively
(Table 2). In other words, the low dose of inhaled bacilli
apparently increased host resistance 3.5-fold (63/18) or the
high dose of inhaled bacilli decreased the host resistance 3.5-
fold. The 12-fold difference in inhaled dose (5,100/310 bacillary
units) would not have affected the alveolar macrophages
(AM), which determine the fate of many of the inhaled bacilli
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during the first few days (see Discussion). Therefore, the 3.5-
fold difference in host resistance was probably due to the effect
of dosage on the host’s native and early acquired immune
responses. This difference in ratio was highly significant (P 5
0.003). The mean ratio in low-dose experiment I gives addi-
tional support to this result (Table 2).
We always thought that early microscopic pulmonary tuber-
cles developed independently of each other, because they were
so small and were usually separated by numerous alveolar
spaces. The influence of the inhaled bacillary dose on the
progression of such microscopic tubercles to grossly visible size
clearly indicates that early-developing tubercles have systemic
effects (see Discussion).
In high-dose experiment II, inbred New Zealand White rab-
bits were used. In low-dose experiments I and III, commer-
cially available noninbred New Zealand White rabbits were
used. Since the inbred rabbits came from the same lineage as
Lurie’s highly resistant Race III rabbits, they needed to inhale
a greater (not smaller) number of tubercle bacilli to produce
one primary lesion. For this reason, the adverse effects of large
numbers of inhaled bacilli were probably somewhat more pro-
nounced than those we observed.
Levels and maintenance of tuberculin sensitivity in rabbits
with TB. (i) Overview. The levels and maintenance of tuber-
culin sensitivity are primarily determined by the number of
bacilli and by the host’s immune response. We did not directly
measure the number of bacilli or the levels of serologic or
cellular immunity, but we did measure the effects of the num-
ber of primary lesions, the number of cavities, and M. vaccae
immunotherapy on tuberculin sensitivity. All of these factors
reflect interactions between the bacillus and the host.
The data from our low-dose experiment III were used with
multiple linear regression analysis. The rabbits in this experi-
ment inhaled about 400 U of the virulent bovine-type bacilli.
They did not die of TB but were sacrificed at 33 weeks before
the disease had run its full course (Table 1) (7). At that time,
the pulmonary lesions showed considerable fibrosis. Therefore,
at least some of the rabbits would probably have arrested their
disease. This slowly progressing TB is similar to that found in
adult humans.
(ii) Effects of the number of primary lesions on tuberculin
sensitivity at 4 weeks. In experiment III, the rabbits were skin
tested with tuberculin 4 weeks after the onset of the infection.
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TABLE 2. Number of inhaled units (of one to three bacilli) that
generate one grossly visible primary pulmonary tuberclea
Expt and no. of
rabbits
Inhaled dose
(bacillary units)
No. of visible primary
pulmonary lesions
(including those with
cavities)
Ratio
I (low dose), 6 523 6 137 6.7 6 2.3 107 6 29
II (high dose), 11 5,100 6 186 310 6 36 18 6 2
III (low dose), 12 418 6 24 8.8 6 1.2 63 6 13
a The numbers of grossly visible primary lesions in the M. vaccae and control
groups, presented in Tables 1, 3, and 4 and in reference 7, were pooled to
prepare this table. The means and their standard errors are listed. The ratio for
each rabbit is the number of inhaled bacillary units required to generate one
grossly visible primary lesion. The means in the ratio column are derived from
ratios for individual rabbits in each experiment and are not derived from the
means listed here. The P values for the ratios are as follows: (i) between exper-
iments I and II, P 5 0.001; (ii) between experiments I and III, P 5 0.124; and (iii)
between experiments II and III, P 5 0.003. Student’s t test was used. The
significant differences in the ratios between experiment II and experiments I and
III indicate that a large number of primary lesions (simultaneously developing in
the lungs) decreased the early immune response or that a small number of
lesions increased this response (see text).
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(M. vaccae immunotherapy was begun afterwards, i.e., at 7
weeks.) The rabbits with few primary lesions had the largest
tuberculin reactions, and, conversely, rabbits with many pri-
mary lesions had the smallest tuberculin reactions (Fig. 1).
By 4 weeks the tuberculin skin reactions for rabbits with the
greatest antigenic stimulus may already have been reduced from
presumably higher peak values, i.e., the down-regulatory mecha-
nisms for tuberculin sensitivity occurred earlier when the anti-
genic load in the host was larger. Alternatively, the rabbits with an
innate ability to reduce the number of grossly visible primary
lesions may have been rabbits that produced a more vigorous
immune response including more sensitivity to tuberculin.
(iii) Effects of the number of primary lesions on the drop in
tuberculin sensitivity between 4 and 33 weeks. In low-dose
experiment III, the mean tuberculin sensitivity decreased over
50% between 4 and 33 weeks (Table 4). The tuberculin sensi-
tivities of rabbits with the largest numbers of primary lesions
decreased the least by 33 weeks (P 5 0.044) (Fig. 2). In other
words, rabbits with more extensive pulmonary TB (i.e., greater
antigenic loads) seemed to maintain their 4-week tuberculin
reactivities better than rabbits with less extensive TB.
A log scale was used in Fig. 2 to show proportional decreases
as straight lines, because the volumes (in cubic millimeters) of
large skin reactions could decrease more than could the vol-
umes of small skin reactions.
(iv) Relationships of tuberculin sensitivity to cavity forma-
tion. After infection of rabbits by aerosolized virulent bovine-
type tubercle bacilli, many of the resulting primary pulmonary
lesions liquefied and cavitated at between 6 and 10 weeks (7).
The studies of Yamamura et al. (56, 57; see reference 16)
indicated that sensitivity to tuberculin was necessary for cavi-
ties to form. In these studies, he injected tubercle bacilli and
their components through the chest wall directly into the lung.
Our aerosol inhalation experiment III provided a more natural
model of TB with which to determine whether or not there was
an association between tuberculin sensitivity and cavity forma-
tion.
We tried to answer two questions. (i) Was the amount of
tuberculin sensitivity at 4 weeks correlated with the percentage
of primary lesions that cavitated by 33 weeks? (ii) Was the
number of cavities (in primary lesions) correlated with the
degree of tuberculin sensitivity at 33 weeks?
Concerning the first question, the tuberculin sensitivity at 4
weeks did not show a statistically significant correlation with
the percentage of primary lesions that cavitated (Fig. 3) (P 5
0.612). These results do not negate Yamamura’s findings be-
cause there was tremendous variability among our individual
rabbits. Our studies did, however, provide a model for future
experiments to address this subject.
Concerning the second question, Fig. 4 shows that rabbits
with large numbers of primary cavities tended to maintain
tuberculin sensitivity at higher levels than did rabbits with
small numbers (P 5 0.059). Although not statistically signifi-
cant, this P value is suggestive. Figure 8 of reference 7 shows
that when both primary and secondary cavities (at 33 weeks)
were added together, a significant correlation between the
number of cavities and the degree of tuberculin sensitivity
existed (P , 0.025).
When liquefaction occurs and cavities form, the bacilli grow
extracellularly in the liquefied caseum of the inner cavity wall
(see Fig. 5, discussed below) and from there spread via the
bronchial tree to other sites in the lung. New lesions that boost
the levels of tuberculin sensitivity are formed. Therefore, one
would expect less decrease in the size of the tuberculin reaction
in animals with more cavities. Another interpretation of our
results would be that cavity formation occurred more fre-
quently in the rabbits innately able to maintain high levels of
tuberculin sensitivity.
Effects of M. vaccae immunotherapy on the extent and pro-
gression of TB. (i) M. vaccae skin lesions. In our experiments
FIG. 1. The relation between the number of primary pulmonary lesions and
the size of the dermal tuberculin reactions in the control and M. vaccae-treated
groups at 4 weeks (in experiment III) before M. vaccae immunotherapy was
begun. The multiple linear regression equation (see Statistics in Materials and
Methods) was y 5 4591.53 2 520.51x1 2 203.67x2, where y is the predicted size
of the tuberculin reaction, x1 equals 1 for the M. vaccae-treated group and 0 for
the control group, and x2 equals the number of primary lesions. (No rabbit failed
to develop primary lesions.) This regression model shows (i) that the slope of the
lines, i.e., the decrease in the mean size of the tuberculin reactions for each
additional primary lesions present, was 203.67 mm3, which was statistically sig-
nificant (P 5 0.015), and (ii) that the difference in the predicted sizes of the
tuberculin reactions between the control and M. vaccae-treated groups was
520.51 mm3, which was not statistically significant (P 5 0.344). R2 was found to
be 0.4524 when the M. vaccae and control data were pooled.
FIG. 2. The relation between the number of primary pulmonary lesions and
the maintenance of tuberculin sensitivity (in experiment III). The maintenance
of tuberculin sensitivity was represented by the ratios of the size of the dermal
tuberculin reactions at 33 weeks to their size at 4 weeks. The ratios were
converted into natural logs (see Table 4). The multiple linear regression equation
(see Materials and Methods) was y 5 21.90 1 0.12x1 1 0.11x2, where y is the
predicted loge of the ratio of the two tuberculin reactions, x1 equal 1 for the M.
vaccae-treated group and 0 for the control group, and x2 equals the number of
primary lesions (see Fig. 1). The graph shows that when more primary lesions
were present tuberculin sensitivity was maintained at higher levels (P 5 0.044).
No statistically significant difference between the M. vaccae-treated and control
groups was found in the maintenance of their predicted tuberculin sensitivities
(P 5 0.747). R2 was found to be 0.4089 when the M. vaccae and control data were
pooled.
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II, III, and IV, the first intradermal injection of M. vaccae was
5, 7, and 9 weeks, respectively, after the rabbits were infected
by aerosol with virulent bovine-type tubercle bacilli (Tables 1
and 5). The skin lesions produced by M. vaccae were well
tolerated. In some tuberculous rabbits, M. vaccae produced a
prominent lesion about 10 mm in diameter with a 1- to 2-mm
central ulcer that healed in about 4 weeks. In other tuberculous
rabbits, the lesions healed without ulceration. We made no
study of whether M. vaccae injections converted the tuberculin
skin tests of tuberculin-negative rabbits.
(ii) Mortality in our high-dose experiment II. To date, ex-
periment II has been our only experiment in which many rab-
bits died or were dying of their TB. None of the five rabbits
that died by 9 weeks had immunotherapy for more than 10
days (Table 3). The six remaining rabbits, two in the control
group and four in the M. vaccae-treated group, survived for 18
weeks (Table 1) (7). There were too few survivors to determine
whether or not M. vaccae had an effect, but the trend was in the
same direction as and consistent with that of the human M.
vaccae trials in which immunotherapy improved the survival
rate (35).
(iii) Effects of M. vaccae on gross pathology and histopathol-
ogy. At the time of necropsy, a slowly progressing cavitary-type
pulmonary TB with considerable fibrosis was present in both
the M. vaccae-treated and the control groups (7). The lesions
of the two groups were also similar in their gross and micro-
scopic characteristics.
The numbers of metastatic lesions in the gut-associated lym-
phoid tissue (GALT) of the appendices and ileocecal junctions
for the M. vaccae-treated and control groups were likewise not
significantly different (Table 1) (P 5 0.567). (The GALT le-
sions apparently came from the bacilli in cavities that ascended
the mucociliary escalator of the bronchial tree and were swal-
lowed.) At necropsy, the weights of the rabbits in the immu-
notherapy and control groups were also comparable (Table 1)
(P 5 0.578).
(iv) Effects of M. vaccae immunotherapy on tuberculin sen-
sitivity. In low-dose experiment III, intradermal injections of
M. vaccae bacilli were given at 7, 12, 17, 22, and 27 weeks after
infection (Table 1). Such immunotherapy had no statistically
significant effect on maintaining the tuberculin reactions at 33
FIG. 4. The relation between the number of primary pulmonary cavities and
the maintenance of tuberculin sensitivities represented by the ratios of the size of
the dermal tuberculin reactions at 33 weeks to their size at 4 weeks (in experi-
ment III). The ratios were converted into natural logs (see Table 4). The multiple
linear regression equation (see Materials and Methods) was y 5 21.24 1 0.25x1
1 0.21x2, where y is the predicted loge of the ratio of the two tuberculin reactions,
x1 equals 1 for the M. vaccae-treated group and 0 for the control group, and x2
equals the number of primary cavities. The graph shows that the tuberculin
sensitivity tended to be maintained at higher levels when more primary cavities
were present (P 5 0.059). No statistically significant difference between the M.
vaccae-treated and control groups was found in the maintenance of their pre-
dicted tuberculin sensitivities (P 5 0.543). R2 was found to be 0.3773 when the
M. vaccae and control data were pooled.
FIG. 3. The relation between the dermal tuberculin sensitivity at 4 weeks and
the percentage of the primary pulmonary lesions that had formed cavities by 33
weeks (in experiment III). The multiple linear regression equation (see Materials
and Methods) was y 5 0.0852 1 0.1782x1 1 0.0000382x2, where y is the predicted
percentage of primary lesions that cavitated by 33 weeks, x1 equals 1 for the M.
vaccae-treated group and 0 for the control group, and x2 is the size of the
tuberculin reaction at 4 weeks. The graph shows (i) that there was no statistically
significant correlation between the 4-week tuberculin sensitivity and the percent-
age of primary pulmonary lesions with cavities at 33 weeks (P 5 0.612) and (ii)
that there was no statistically significant difference between M. vaccae-treated
and control groups in the percentage of primary lesions that cavitated (P 5
0.291). R2 was found to be 0.3188 when the M. vaccae and control data were
pooled. See Results for the importance of these findings.
TABLE 3. Pulmonary TB in rabbits dying of TB in high-dose experiment IIa
Treatment
(rabbit no.)
Approximate time of death
(or sacrifice) (wk)
No. of inhaled virulent
bacillary units
No. of visible primary
lesions in lungsb
No. of
cavities Comments
Control (2) 5 4,800 550 0 Numerous 3- to 4-mm-diam lesions with
minute caseous centers
M. vaccae (9) 6 5,800 210 Many Over half of the lesions had cavitated
Control (11) 7 4,700 260 Many Over half of the lesions had cavitated
Control (10) 8.5 3,900 250 Many Over half of the lesions had cavitated
Control (4) 9 5,300 500 Many Numerous cavities were present
a These 5 dead or dying rabbits were not included in reference 7. Ten days before death, rabbit 9 was given one M. vaccae injection. This injection was probably
ineffectual in such a nearly terminal rabbit. The remaining six rabbits of this high-dose experiment were sacrificed at 18 weeks, and details of their necropsies were
presented in Table 1 of reference 7.
b Includes primary lesions with cavities.
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weeks (Fig. 2 and 4), i.e., the immunotherapy had little tuber-
culin-sensitizing power (if any). In Fig. 2, the x axis represents
the number of primary lesions (including cavities). In Fig. 4,
the x axis represents the number of primary cavities. Both
figures show that the tuberculin sensitivities of rabbits receiv-
ing M. vaccae were not statistically different from those of the
controls (P 5 0.747 and 0.543 for Fig. 2 and 4, respectively).
Multiple linear regression statistical analyses were necessary,
because the numbers of primary lesions and primary cavities
affect the degree of tuberculin sensitivity and could obscure
whatever effect M. vaccae immunotherapy might have had.
That M. vaccae did not appreciably affect the tuberculin
sensitivities of the tuberculous rabbits is similar to what was
found for humans (8, 35, 50): in individuals with active TB, M.
vaccae injections were a consistently safe therapeutic measure
because the M. vaccae (unlike Koch’s tuberculin “therapeutic”
injections [25]) did not cause systemic hypersensitivity reac-
tions (8, 35, 50).
(v) Effects of M. vaccae immunotherapy on cavity formation.
The mean numbers of primary lesions (including those that
formed cavities) for the M. vaccae-treated and control groups
were comparable: 8.0 6 1.9 and 9.5 6 1.5 lesions, respectively
(Table 4). The mean numbers of these primary cavitary lesions
that cavitated in the M. vaccae-treated and control groups were
3.0 6 0.9 and 1.8 6 0.8, respectively (Table 4). However, due
to the large variation among the rabbits, the difference in these
means was not statistically significant (P 5 0.341). The per-
centage of primary lesions that cavitated is a better index of M.
vaccae’s effect on cavitation (Table 4 and Fig. 3). It averaged
35.7% 6 11.9% for the M. vaccae-treated group and 18.7% 6
9.5% for the control group. However, the large variability
within the two groups showed that again this difference was of
no statistical significance (P 5 0.291). If we assume that the
difference between the average percentages for the two groups
(35.7% 2 18.7%) was truly 17.0%, then 350 rabbits (175 1
175) would be required to produce a result that would be
statistically significant at the 95% certainty level. (For this
computation, we have treated the data as simple random sam-
ples and used an a error of 0.05 [two-tailed] and a b error of
0.05 [one-tailed]).
Although the P values were high enough to assure us that
the observed M. vaccae effect on cavity formation was a chance
phenomenon, the difference in means is a bit worrisome. Cav-
ity formation is an immune reaction (16, 56, 57) that is a major
cause of the spread of tubercle bacilli from person to person as
well as a major factor in the development of multidrug-resis-
tant strains of bacilli. (They multiply profusely [and extracel-
lularly] in the well-oxygenated cavity wall [Fig. 5].) An immu-
notherapeutic agent that favors cavity formation would definitely
be contraindicated.
(vi) Number of bacilli in liquefied and cavitary lesions: its
variability masked any M. vaccae effect. In most lesions with
liquefied centers, appreciable numbers of acid-fast bacilli were
visible microscopically (7, 26), but in lesions with solid caseous
centers only a few bacilli were visible (26). The number of
bacilli probably increases substantially after cavities form.
However, to date no careful comparisons between the number
of bacilli in the liquefied caseum of cavitary lesions and the
number of bacilli in the liquefied caseum of noncavitary lesions
have been made. The increased oxygen provided by the con-
nection to the bronchial tree has always been considered to be
a stimulus for bacillary multiplication (26), and Fig. 5B clearly
demonstrates this phenomenon: the most numerous bacilli ex-
ist in the liquefied caseum adjacent to the air within the cavity.
TABLE 4. Primary lesions, cavities, and tuberculin skin tests in the rabbits of low-dose experiment IIIa
Rabbit no.
Total no. of primary
lesions (including
cavitary lesions)
No. of primary
lesions with
cavities
% Primary lesions
that cavitated
Dermal tuberculin sensitivityb
in mm3 (loge) at:
% Tuberculin
sensitivity for
33 vs 4 week
(loge)4 wk 33 wk
M. vaccae-treated rabbits
2 13c 5c 38 1,890 (7.54) 1,200 (7.09) 63.5 (20.45)
4 14 4 29 1,040 (6.90) 1,660 (7.42) 159.6 (10.47)
6 2 0 0 3,500 (8.16) 630 (6.43) 18.0 (21.72)
7 7 1 14 1,900 (7.55) 650 (6.48) 34.2 (21.07)
9 6 5 83 4,700 (8.46) 1,050 (6.96) 22.3 (21.50)
12 6 3 50 1,620 (7.39)
Mean 6 SE 8.0 6 1.9 3.0 6 0.9d 35.7 6 11.9e 2,606 6 562f 1,038 6 191 59.5 6 26.3g
Control rabbits
1 15 3 20 1,890 (7.54) 1,420 (7.26) 75.1 (20.29)
3 4 0 0 4,500 (8.41) 1,660 (7.42) 36.9 (21.00)
5 8c 5c 63 2,600 (7.86) 2,700 (7.90) 103.8 (20.04)
8 9 1 11 2,700 (7.90) 810 (6.70) 30.0 (21.20)
10 10 0 0 1,850 (7.53) 500 (6.22) 27.0 (21.31)
11 11 2 18 2,400 (7.78) 610 (6.41) 25.4 (21.37)
Mean 6 SE 9.5 6 1.5 1.8 6 0.8d 18.7 6 9.5e 2,657 6 396) 1,283 6 340 49.7 6 13.2g
a Note that the data in this table differ from those in Fig. 8 of reference 7. In Fig. 8A, the number of cavitary lesions should have included primary lesions that had
formed cavities but did not. And in Fig. 8B, the total number of cavities formed by both primary and secondary TB lesions was plotted, not just the number of cavities
formed by primary lesions.
b The mean tuberculin sensitivity at 33 weeks is 39.8% of the mean sensitivity at 4 weeks for M. vaccae-treated rabbits; the corresponding value for control rabbits
is 48.3%.
c Estimate; see the text.
d Student’s t test showed no statistically significant differences between the M. vaccae-treated and control groups (P 5 0.341).
e See footnote d. P 5 0.291.
f Mean without rabbit 12; the mean with rabbit 12 is 2,442 mm3.
g See footnote d. P 5 0.732.
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FIG. 5. (A) Tissue section of a pulmonary tuberculous lesion of M. vaccae-treated rabbit 4 in low-dose experiment III showing tubercle bacilli that had grown
profusely in the liquefied caseum. This lesion was probably beginning to cavitate because some of the spaces in the liquefied caseum were larger than usual. Such profuse
growth occurs only in some lesions with liquefied centers, presumably where the composition of the liquefied caseum is most favorable and/or the adaptation of the
bacillus to extracellular growth is most complete. Carbol-fuchsin, counterstained with methylene blue. Magnification, 3600. (B) Tissue section of the wall of a
pulmonary cavity of control rabbit 5 in low-dose experiment III showing tubercle bacilli that had grown profusely in the liquefied caseum. The bacilli are more numerous
near the lumen of the cavity (on the left), presumably because the oxygen tension there is highest. As stated in the legend for panel A, such profuse growth occurs only
in the walls of some, not all, cavities. Carbol-fuchsin, counterstained with methylene blue. Magnification, 3250.
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The multiplication of tubercle bacilli within individual liq-
uefied caseous lesions is extremely variable (7), probably de-
pending on the composition of the liquefied caseum and on the
rate at which the bacilli adapt to the new extracellular envi-
ronment. Because of this variability, the effects of M. vaccae
immunotherapy on the extracellular growth of tubercle bacilli
could not be determined.
(vii) Experiment IV: immunotherapy with 1/10 the human
dose of M. vaccae. Because the human dose of 109 M. vaccae
cells may have been excessive for rabbits, a small pilot-type
experiment was performed at Texas A & M University. In this
experiment 108 M. vaccae baccilli (1/10 the human dose) was
given intradermally at 9 and 13 weeks after the rabbits inhaled
about 1,000 U of one to three virulent M. bovis bacilli (Ravenel
S). The inhaled dose was intermediate between those in ex-
periments II and III (Tables 1 and 5). The Texas A & M
aerosol exposure system is described in references 32 and 54.
Three rabbits received M. vaccae, and two received diluent
alone. When the rabbits were sacrificed at 19 weeks, the M.
vaccae-treated group had fewer and smaller primary lesions
and fewer secondary lesions (Table 5). The low number of
primary lesions in the M. vaccae-treated group was probably
not due to immunotherapy, because such therapy began at 9
weeks, long after these lesions were well established. (Grossly
visible primary pulmonary lesions produced by virulent Myco-
bacterium bovis in rabbits have never been shown to regress
[26]). The reduced size of the primary lesions and the lower
number of secondary pulmonary lesions could have been due
to M. vaccae immunotherapy, but such differences from the
control group were not statistically significant. These sugges-
tive results are, however, consistent with those found in human
M. vaccae trials (see Discussion).
DISCUSSION
Rabbit model. Pulmonary TB in rabbits (7, 9, 11, 15, 26) can
be an excellent model for TB in human beings (17), in that
both species are relatively resistant to TB and both species
readily form liquefied caseous foci and cavities. Neither species
is inbred, so considerable variation in the amount and extent of
the disease occurs. Much variation among the individual le-
sions within a given host also occurs (7). These factors make
studies of both rabbits and humans more difficult and more
expensive than studies of inbred mice, but cavitary TB cannot
be produced in mice and only rarely in guinea pigs.
Virulence of the tubercle bacillus, strain Ravenel S (ATCC
35720). This Ravenel S strain of virulent bovine-type tubercle
bacilli was not fully virulent. With fully virulent (bovine-type)
Ravenel S tubercle bacilli, one-third of the bacillary units in-
haled produce one grossly visible tubercle in both resistant and
susceptible inbred rabbits (1, 26, 27, 30). With Ravenel S, 18 to
107 inhaled bacillary units were required to produce one
grossly visible primary pulmonary tubercle (Table 2). About
every 5 to 10 years, Lurie (26) maintained the full virulence of
the Ravenel S strain that he used by infecting rabbits and
recovering the bacilli from the tuberculous lesions produced.
This procedure was successful because only the most virulent
bacilli seemed to survive in such lesions after the immune
response developed.
The ATCC personnel kept Ravenel S lyophilized after they
received it from the Trudeau Mycobacterial Culture Collection
in 1985 (see Materials and Methods). It was obtained in 1910
from M. P. Ravenel of the University of Wisconsin in Madison.
Ravenel had isolated it from a tuberculous bovine. At the
Trudeau Institute, it was periodically cultured on Proskauer-
Beck solid media until 1970, when it was rapidly frozen and
stored (unlyophilized) at 270°C until it was sent to ATCC. At
the Trudeau Institute, the infection of mice, guinea pigs, and
rabbits was used to study virulence, and strains of reduced
virulence were usually replaced by bacilli from early cultures
that had been stored in a frozen state. However, the aerosol
method of infection and subsequent pulmonary tubercle
counts (12) were not apparently used for virulence testing.
This history was supplied by Frank M. Collins, Mycobacte-
rial Laboratory, Center for Biologics Evaluation and Research,
U.S. Food and Drug Administration, Rockville, Maryland, and
from reference 5a. The repeated subculturing could have re-
duced the virulence of the Ravenel S strain for rabbits, but
lyophilization was the most likely cause. Lyophilization appar-
ently reduced the virulence of H37Rv mycobacteria in the
mouse (6).
The initial (very early) immune response. The initial im-
mune response determines whether a microscopic pulmonary
tubercle develops into a grossly visible tubercle, if the infecting
strain of tubercle bacillus is not 100% virulent for the species
involved (which is the case for humans). The studies herein
reported provide new insight into this early host immune re-
sponse.
In the lung, each site of bacillary lodgment is usually sepa-
rated by numerous alveolar spaces. Therefore, we always
thought that early sites of infection were completely indepen-
dent of each other. However, Table 2 shows (i) that large
numbers of developing lesions had systemic effects that appar-
ently reduced the efficacy of the host’s early innate and ac-
quired immune responses or (ii) that low numbers of develop-
ing lesions had systemic effects that increased the efficacy of
these responses.
The efficacy of alveolar macrophages (AM) could not have
been reduced or increased, because AM determine the fate of
the developing lesion only during the first few days before the
blood-borne monocytes/macrophages take over (9, 10, 15, 17).
AM are highly activated macrophages (14). They are appar-
ently activated by the continuous ingestion of a variety of
inhaled particles (18). The ability of these phagocytes to de-
TABLE 5. Data from experiment IV, in which 1/10 the human dose of M. vaccae bacilli was used for immunotherapya
Treatment
(rabbit no.)
Approximate inhaled
dose (bacillary units)
No. of visible primary
pulmonary lesions Ratio
Avg diam of primary pulmonary
lesions (mm)
No. of secondary
pulmonary lesions
M. vaccae (1) 1,000 28 35.7 2.4 30
M. vaccae (2) 1,000 30 33.3 2.5 125
M. vaccae (3) 1,000 41 24.4 3.0 35
Control (4) 1,000 58 17.2 5.7 .40
Control (5) 1,000 103 9.7 3.0 Several hundred
a In this pilot study, the rabbits were infected with virulent bovine-type tubercle bacilli (Ravenel S). At both 9 and 13 weeks, they were injected intradermally with
108 heat-killed M. vaccae cells, and at 19 weeks they were sacrificed. The ratio is the number of inhaled bacilli required to generate one grossly visible primary lesion
(mean 6 standard error 5 24 6 5). Note that the inhaled dose and the ratios are intermediate between those listed in Table 2.
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stroy or inhibit tubercle bacilli exists before the infection be-
gins and would not be influenced by a large or small inhaled
bacillary dose.
Therefore, the large inhaled dose of bacilli must have af-
fected the blood-borne macrophages that control the fate of
the very early tubercle after the AM cease to play a role.
Blood-borne macrophages are activated (i) by the host’s innate
immune response, i.e., by natural killer cells and the gamma
interferon (IFN-g) that they produce (23, 33), and (ii) by the
host’s acquired immune response, i.e., by Th1 lymphocytes (34,
36) and the cytokines (including the IFN-g) that they produce
(17). Once activated, the blood-borne macrophages can also
inhibit the intracellular growth of the bacillus, thereby prevent-
ing some of the early microscopic tubercles from reaching
grossly visible size.
Thus, both the AM and the infiltrating blood-borne mono-
nuclear cells, including natural killer cells, lymphocytes, mac-
rophages, and probably dendritic cells, can together stop in-
haled tubercle bacilli from producing grossly visible pulmonary
lesions (12). Once established, grossly visible tubercles can
heal with fibrosis, stabilize, or progress, but they will usually be
recognizable at necropsy, even years later.
The dose effects discussed above were probably due to
changes in the Th1/Th2 lymphocyte ratios, as first described by
Bretscher et al. (5). After being infected with a very low dose
of Leishmania major, fully susceptible BALB/c mice produced
a “resistant” Th1 response and survived. After a standard dose,
such mice always produced a “susceptible” Th2 response and
succumbed to the infection. The low infecting doses of L.
major apparently locked in the beneficial Th1 response, so
much so that these BALB/c mice could survive a subsequent
challenge with the standard dose of L. major (5).
Because only few bacilli are usually inhaled over a period of
months, pulmonary TB in most human beings begins as a
single primary tubercle. This initial low dose would favor a high
Th1/Th2 ratio, a fact which partly explains why humans usually
must inhale an estimated 20 to 200 bacillary units before they
develop the disease.
Unfortunately, Lurie (26) did not expose his susceptible and
resistant strains of rabbits to very low aerosolized doses of
tubercle bacilli, but he did prove that the very early developing
primary pulmonary lesions were controlled by systemic factors.
Decreasing the immune response by cortisone treatment in-
creased the number of such grossly visible lesions (29), prob-
ably (at least in part) due to a decrease in the Th1/Th2 ratio
(19, 37). Increasing the immune response by a previous vacci-
nation with M. bovis BCG decreased the number of primary
lesions that were grossly visible 5 weeks after the inhalation of
virulent human-type tubercle bacilli (28). In this BCG experi-
ment, many primary microscopic tubercles were evidently
eliminated or arrested by the developing immune response
before they became grossly visible. In fact, such early immune-
mediated inhibition of bacillary growth is the way in which
clinically evident disease is prevented by vaccination. The de-
struction of tubercle bacilli by AM is immunologically nonspe-
cific and would not be increased after the nonspecific adjuvant
effects of the vaccine have subsided.
All of these studies indicate that systemic factors affect the
progression and regression of early-developing primary tuber-
cles. In these tubercles, the ratio of Th1 to Th2 lymphocytes
appears to be under systemic control. Studies of the composi-
tion and functions of peripheral blood mononuclear cells
(monocytes and lymphocytes) (20–22, 52) may therefore give
some indication of what is occurring in the local tuberculous
lesions. However, it remains to be investigated whether micro-
scopic primary tubercles that regress or stabilize have a higher
local Th1/Th2 ratio than do microscopic primary tubercles that
progress to a grossly visible size.
Tuberculin sensitivity in hosts with stabilized disease. The
studies reported herein show that rabbits and human beings
probably differ in maintaining their tuberculin sensitivity as
well as in the amount of this sensitivity. In humans, when TB
is not extensive, the tuberculin sensitivity seems to be main-
tained at rather high levels for years, even after the disease has
regressed or stabilized (7a). In the rabbits of our low-dose
experiment III, the peak tuberculin sensitivity was not main-
tained at high levels, even though their pulmonary TB was
stabilized or only slowly progressing at 33 weeks, and they
appeared overtly healthy (Table 4). This decrease in tuberculin
sensitivity is consistent with what is found for many immuno-
logic reactions, which peak and then regress. Unfortunately, no
sequential study of tuberculin reactions in humans with TB
seems to have been made. Once such a patient is found to be
tuberculin positive, further skin tests are usually stopped be-
cause of the danger of severe reactions (including necrosis) at
the test site. Thus, we have no information on whether tuber-
culin sensitivity peaked and partly regressed in patients whose
TB was well controlled, but we do know that it remains strong
for many years.
Humans are at least 100 times more sensitive to tuberculin
than are rabbits (unpublished experiments from our laboratory
with 250 tuberculin units of purified protein derivative [PPD]).
(Guinea pigs are only about two times more sensitive than
rabbits to tuberculin [26a].) The differences in the tuberculin
sensitivities of rabbits and humans (when both are infected
with tubercle bacilli) may be due to differences in their diets
and in their bowel physiologies. Wild rabbits are in constant
contact with the soil mycobacteria, and even laboratory rabbits
are probably exposed to such mycobacteria. Their diet in the
wild consists of uncooked vegetation, and sometimes in cap-
tivity raw vegetables are included. Rabbits have a huge cecum,
a blind pouch (8 to 9 in. long and about 1 in. in diameter) that
ends in a well-developed appendix. In this cecum, bacteria
break down the vegetable cellulose providing nourishment for
the host. Therefore, soil mycobacteria probably exist in the
bacterial flora of the cecum and other parts of the rabbit
intestine (44).
Group I (common) antigens are produced by all mycobac-
teria (46). Group II antigens are produced by all slow-growing
mycobacteria including both virulent TB bacilli and slow grow-
ers from the soil (31, 45, 46), and group II antigens are major
components of tuberculin, including PPD (31, 45). Rabbits are
continuously exposed to the group II antigens in the intestines
and probably become at least partially desensitized to these
antigens (45). They remain sensitive, however, to the group IV
species-specific antigens of virulent mycobacteria (45). These
concepts may explain why tuberculous rabbits react more
weakly than humans to tuberculin and why their tuberculin
skin tests may not be maintained as well as those of infected
human beings. They also imply that the group II antigens
(present in both virulent and nonvirulent tubercle bacilli) are
important in maintaining in human beings both tuberculin
sensitivity and the resistance produced by BCG vaccination
(31, 44, 45).
In humans with extensive TB, the tuberculin reactions may
become negative (20–22, 52). In our high-dose experiment II,
rabbits with extensive TB had tuberculin reactions that were
about one-third the size of those of rabbits in low-dose exper-
iment III with less extensive TB (Table 1). These findings
indicate that extensive pulmonary TB can reduce the tubercu-
lin reactions in both rabbits and human beings.
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Effects of M. vaccae immunotherapy. In tuberculin-negative
healthy humans, injections of M. vaccae usually did not convert
the PPD skin test (53). Also, BCG mixed with M. vaccae
produced the same percentage of positive PPD skin tests as did
BCG alone (2), but the diameters of the skin reactions tended
to be smaller in people receiving the mixture (4).
Studies of M. vaccae effects in humans have involved much
larger numbers of individuals than are practical with rabbits,
and statistically significant results were obtained (8, 35, 47, 50).
A single injection of 109 M. vaccae bacilli (given early during
antimicrobial therapy) halved the treatment failure rates and
reduced the death rates. Repeated injections of M. vaccae at
2-month intervals appeared promising in patients with multi-
drug-resistant TB, in patients coinfected with human immuno-
deficiency virus, and in patients receiving inadequate antimi-
crobial therapy (49). M. vaccae also improved the patients’
clinical condition and helped clear the sputum of bacilli. These
effects were thought to be due to the enhancement of the ratio
of Th1 lymphocytes to Th2 lymphocytes (40–42) and to the
decrease in the amount of tissue destruction caused by the
Koch phenomenon (24, 38, 40–42, 47). In these human studies,
a reduction in tuberculin sensitivity was produced by M. vaccae
immunotherapy (48), and this reduction was again considered
to be due to the enhancement of the Th1/Th2 cell ratio.
Yamamura (57) showed that no cavities developed in rabbits
desensitized to a tuberculin-active peptide. Therefore, a de-
crease in tuberculin sensitivity produced by M. vaccae might
reduce the progression of existing cavities and reduce the for-
mation of new cavities. The above-listed favorable effects for
the host were evidently produced by group I antigens common
to M. vaccae and Mycobacterium tuberculosis coupled with the
absence in M. vaccae of the species-specific antigens present in
M. tuberculosis (40–42, 47, 48).
In our M. vaccae rabbit experiments, no antimicrobial drugs
were administered, whereas in the human M. vaccae trials
antimicrobials were simultaneously given. This difference in
experimental design may have partly contributed to our inabil-
ity to confirm in rabbits the results of the human trials that
showed M. vaccae immunotherapy to be beneficial.
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